Latest Breaking News On - Wadi mor - Page 1 : comparemela.com

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics : Notice and Proxy Statement with respect to the Company's annual general meeting of the shareholders (the "Meeting") to be held on June 10, 2024, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting - Form 6-K

May 3, 2024 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially.

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab Awarded New European Patent for CM-101, Its

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories..

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis Further Extends Protections Afforded by.